)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Adverum Biotechnologies
Adverum Biotechnologies (ADVM) investor relations material
Adverum Biotechnologies has been acquired by Eli Lilly and Company
Adverum Biotechnologies Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary12 Nov, 2025
Executive summary
Entered into a merger agreement with Eli Lilly, including a tender offer and contingent value rights (CVRs) for shareholders, with the merger expected to close in Q4 2025.
Lead product candidate Ixo-vec advanced to Phase 3 trials for wet AMD, with full enrollment for ARTEMIS expected in Q4 2025 and top-line data in Q1 2027.
Substantial doubt exists regarding ability to continue as a going concern, with cash and equivalents insufficient to fund operations for 12 months without additional financing or merger completion.
Financial highlights
Cash, cash equivalents, and short-term investments totaled $26.1 million as of September 30, 2025, down from $125.7 million at December 31, 2024.
Net loss for Q3 2025 was $47.7 million, compared to $32.4 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $143.9 million, up from $90.0 million in the prior year period.
Operating expenses increased to $48.0 million in Q3 2025 (from $35.4 million in Q3 2024), primarily due to higher R&D spending on Ixo-vec Phase 3 activities.
Cash used in operations for the nine months ended September 30, 2025 was $109.7 million.
Outlook and guidance
Cash, equivalents, and advances under the secured note with Lilly are expected to fund operations through the anticipated merger close.
If the merger is not completed, additional financing will be required; failure to secure funding may result in bankruptcy or liquidation.
ARTEMIS Phase 3 trial full enrollment expected in Q4 2025, with top-line data in Q1 2027; AQUARIUS Phase 3 trial initiation planned for Q4 2025.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Adverum Biotechnologies
- Shareholders will vote on director elections, auditor ratification, executive pay, equity plan, and option repricing.ADVM
Proxy Filing - Stockholders will vote on director elections, auditor ratification, compensation, equity plan changes, and repricing.ADVMProxy Filing
- Gene therapy Ixo-vec achieves high injection-free rates and prepares for phase III launch.ADVMUBS Virtual Ophthalmology Day
- Ixo-vec delivers durable efficacy, high injection-free rates, and strong patient preference in wet AMD.ADVMStatus Update
- Ixo-Vec achieved best-in-class injection-free rates and is advancing to phase III in 2025.ADVMH.C. Wainwright 26th Annual Global Investment Conference 2024
- Gene therapy achieves durable, injection-free vision preservation in wet AMD, with strong patient preference.ADVMH.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Ixo-vec achieved up to 95% injection-free rates, maintained vision, and had high patient preference.ADVMStudy Update
- Ixo-vec demonstrates durable efficacy and safety, with phase III enrollment underway and strong patient demand.ADVMRBC Inaugural Virtual Ophthalmology Conference
- Ixo-vec gene therapy enables long-term injection freedom and vision gains for wet AMD patients.ADVMTD Cowen 45th Annual Healthcare Conference
- Gene therapy for wet AMD achieves high injection-free rates and advances to phase III.ADVMOppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Adverum Biotechnologies
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Adverum Biotechnologies Inc, originally known as Avalanche Biotechnologies Inc, is a clinical-stage gene therapy company based in Redwood City, California. Focused on addressing unmet medical needs, the company targets serious ocular and rare diseases, including wet age-related macular degeneration (wet AMD). It leverages its proprietary intravitreal (IVT) platform to develop durable, single-administration therapies intended to be delivered in physicians' offices. This approach aims to transform the standard of care for highly prevalent ocular diseases by eliminating the need for frequent ocular injections. The company is headquartered in Redwood City, California, and its shares are listed on the Nasdaq.